{
 "context": "The following article called 'Eli Lilly Chief Says China Too Slow in Approving New Drugs' was published on 2012-11-28. The body of the article is as follows:\n    \nChina takes eight years longer on\naverage to approve drugs than other major countries and U.S.\ndrugmakers are looking at ways to help speed things up,  Eli\nLilly & Co. (LLY)  Chief Executive Officer  John Lechleiter  said.  \u201cThis is a drug lag that I hope we are able to close in\nthe coming years, by working with Chinese authorities to speed\nup the process of doing clinical trials in China,\u201d Lechleiter\nsaid in an interview in Beijing yesterday. The 59-year-old\nexecutive is spending the week in China to meet government\nofficials and business executives as chairman of the industry\ngroup  Pharmaceutical Research and Manufacturers of America .  Lilly itself plans to conduct simultaneous late-stage tests\nin China for products such as the experimental diabetes drug\ndulaglutide, according to Lechleiter. The Indianapolis-based\ndrugmaker wants introduce more than a dozen medicines in China\nin the next five years, including drugs for diabetes and cancer,\nand seeks to keep sales there growing 25 percent as they did\nlast year, he said in March.  Drugmakers are working to expand their offerings in  China ,\nthe world\u2019s fastest-growing pharmaceuticals market, as revenue\ndrops elsewhere, hurt by expiring patents on blockbusters. Lilly\nin October said quarterly earnings had missed analyst estimates\nafter generic competition hurt revenue from the schizophrenia\ntreatment Zyprexa, once the company\u2019s top-selling drug.  Lechleiter said \u201cprospects are good\u201d for further\nexpansion of Lilly\u2019s drug-manufacturing operations in China. The\ncompany opened a second plant in June this year in the eastern\ncity of Suzhou.  To contact Bloomberg News staff for this story:\nDaryl Loo in Beijing at \n dloo7@bloomberg.net   To contact the editor responsible for this story:\nJason Gale at \n j.gale@bloomberg.net\n\n    The day before the article was published, the stock price of Eli Lilly and Company was 37.881187438964844 and the day after the article was published, the stock price of Eli Lilly and Company was ",
 "expected": "38.596229553222656",
 "date": "2012-11-28",
 "ticker": "LLY",
 "company": "Eli Lilly and Company",
 "url": "http://www.bloomberg.com/news/2012-11-28/eli-lilly-chief-says-china-too-slow-in-approving-new-drugs.html"
}